Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (ASX:RCE) develops anti-infectives for a range of issues and post-surgical complications
- The company has now won a patent in Canada
- Its lead drug R327 is both injectable and applicable as a gel
- Shares last traded at 45 cents
Recce Pharmaceuticals (ASX:RCE) has announced its receipt of a patent for its anti-infective drugs in Canada.
Its new class of synthetic anti-infectives is led by the flagship piper of the pack – Recce’s R327.
The drug has been shown to be a superior UTI treatment compared to conventional existing medicines in trials.
Recce’s Canada IP locked in
The same drug, as a gel, has also shown early-stage evidence of being a successful treatment in diabetic patients who experience post surgical infections.
And now R327 is coming to Canada.
Its patent in the jurisdiction permits the company to patent its process for preparing the treatment and to patent multiple administration pathways.
Oral, inhalation, transdermal and injection-based forms of the drug are now Recce’s IP in Canada.
Green tick for medical trials
The company has also won the right to use the drug in tests in Canada.
Recce Pharmaceuticals has directed R327 into studies looking at burn wounds, UTIs, gonorrhoea, and the flu and COVID-19.
“We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” RCE CEO James Graham said.
“This achievement further extends our global patent portfolio and comes as a welcome new set of marketing/manufacturing monopolies in Canada, to at least January 2041.”
RCE shares last traded at 45 cents.
